Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 9128 results

  1. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development Reference number: GID-TA11422 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  2. Orforglipron for managing overweight and obesity [ID6516]

    In development Reference number: GID-TA11650 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  3. Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]

    Awaiting development Reference number: GID-TA11855 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [ID6755]

    Awaiting development Reference number: GID-TA11974 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. OCU400 for treating retinitis pigmentosa in people 5 years and over [ID6687]

    Awaiting development Reference number: GID-TA11905 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease ID6733: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 11 August 2026.

    Technology appraisal guidance
    In consultation

  7. Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease ID6733

    In development Reference number: GID-TA11945 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

    In development Reference number: GID-TA11552 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  9. Artificial intelligence (AI) technologies to help detect prostate cancer on MRI

    In development Reference number: GID-HTG10879 Expected publication date:  12 November 2026

    HealthTech guidance
    In development

  10. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  11. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  04 September 2026

    Technology appraisal guidance
    In development

  12. Self-directed automated audiometry for the diagnosis of hearing loss in adults (provisional title)

    In development Reference number: GID-HTG10909 Expected publication date: TBC

    HealthTech guidance
    In development

  13. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    Awaiting development Reference number: GID-TA11274 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Technology appraisal guidance Reference number: TA1177 Published:  14 July 2026

    Technology appraisal guidance
    Awaiting development

  15. Osimertinib for adjuvant treatment of EGFR mutation-positive stage 1A2 or 1A3 non-small-cell lung cancer after complete tumour resection

    Awaiting development Reference number: GID-TA12457 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development